Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Abdominal pain in a patient with acute lymphoblastic leukaemia.

Breitenstein A, Kühne R, Minder EI, Marek A, Goede J, Schanz U, Renner C.

Ann Hematol. 2010 Feb;89(2):211-2. doi: 10.1007/s00277-009-0789-4. Epub 2009 Jul 9. No abstract available.

PMID:
19588138
2.

Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.

Sonmez M, Cobanoglu U, Ovali E, Omay SB.

J Clin Pharm Ther. 2008 Jun;33(3):329-30. doi: 10.1111/j.1365-2710.2008.00916.x. No abstract available.

PMID:
18452422
3.

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

Fava C, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. No abstract available.

PMID:
24290212
4.

Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Satake A, Okada M, Asada T, Fujita K, Ikegame K, Tamaki H, Fujimori Y, Ogawa H.

Leuk Lymphoma. 2010 Oct;51(10):1920-2. doi: 10.3109/10428194.2010.509453. No abstract available.

PMID:
20858093
5.

Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.

Ohta S, Najima Y, Imamura J.

Br J Haematol. 2015 Jun;169(5):612. doi: 10.1111/bjh.13407. Epub 2015 Apr 8. No abstract available.

PMID:
25855138
6.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

Klyuchnikov E, Schafhausen P, Kröger N, Brummendorf TH, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuk F, Zander AR, Bacher U.

Acta Haematol. 2009;122(1):6-10. doi: 10.1159/000228587. Epub 2009 Jul 15. No abstract available.

PMID:
19602874
7.

Dasatinib: for some difficult cases of adult leukaemia.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):149-50. No abstract available.

PMID:
19496239
8.

Dasatinib (Sprycel) for CML and Ph + ALL.

[No authors listed]

Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7. No abstract available.

PMID:
17220814
9.

Circumventing resistance to kinase-inhibitor therapy.

Druker BJ.

N Engl J Med. 2006 Jun 15;354(24):2594-6. No abstract available.

PMID:
16775240
11.

Dasatinib.

Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P.

Nat Rev Drug Discov. 2006 Sep;5(9):717-8. No abstract available.

PMID:
17001803
12.

Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.

Santos FP, Rodrigues M, Mac-Donald Bley do Nascimento C, Kerbauy FR, Ribeiro AA, Mauro Kutner J, Hamerschlak N.

Cytotherapy. 2010;12(1):113-5. doi: 10.3109/14653240903300666. No abstract available.

PMID:
19878083
13.

Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.

Brazzelli V, Grasso V, Barbaccia V, Manna G, Rivetti N, Zecca M, Giorgiani G, Vassallo C, Borroni G.

Acta Derm Venereol. 2012 Mar;92(2):218-9. doi: 10.2340/00015555-1289. No abstract available.

14.

Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, Arras M, Atzeni S, Littera R, La Nasa G.

Biol Blood Marrow Transplant. 2012 Apr;18(4):652-4. doi: 10.1016/j.bbmt.2011.12.587. Epub 2012 Jan 9. No abstract available.

15.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F.

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15. No abstract available.

PMID:
19075254
16.

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Gruber F, Mustjoki S, Porkka K.

Br J Haematol. 2009 Jun;145(5):581-97. doi: 10.1111/j.1365-2141.2009.07666.x. Epub 2009 Apr 15. Review.

PMID:
19388927
17.

Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours.

Bhadri VA, Satharasinghe K, Sugo E, Barbaric D, Trahair TN.

Br J Haematol. 2011 Feb;152(3):347-9. doi: 10.1111/j.1365-2141.2010.08465.x. Epub 2010 Dec 13. No abstract available.

PMID:
21155759
18.

Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Kim JC, Shin SH, Yi HG, Kim SH, Woo SI, Kim DH, Park KS, Kwan J.

Herz. 2013 Dec;38(8):931-3. doi: 10.1007/s00059-013-3765-7. Epub 2013 Feb 23. No abstract available.

PMID:
23430094
19.

Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.

Abruzzese E, Del Poeta G, Barbato R, Fratoni S, Trawinska MM, Zangrilli D, Coletta AM, Patroi IM, Francesconi F, Santeusanio G, De Fabritiis P, Amadori S.

Blood. 2006 Jun 1;107(11):4571-2. No abstract available.

20.

Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.

Millot F, Cividin M, Brizard F, Chomel JC, Méchinaud F, Guilhot F.

Pediatr Blood Cancer. 2009 Jul;52(7):891-2. doi: 10.1002/pbc.21938.

PMID:
19202569

Supplemental Content

Support Center